How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?

YUE, Wenjie; Liu, Yi; LI, Xiang; HUANG, Jianping; CHEN, Tao; LYU, Liyuan

How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?

Jianping HUANG, (Department of Gastroenterology, Huashan Hospital Affiliated to Fudan University, Shanghai, China)

Tao CHEN, (Department of Gastroenterology, Huashan Hospital Affiliated to Fudan University, Shanghai, China)

Yi LIU, (Department of Gastroenterology, Huashan Hospital Affiliated to Fudan University, Shanghai, China)

Liyuan LYU, (Department of Gastroenterology, Huashan Hospital Affiliated to Fudan University, Shanghai, China)

Xiang LI, (Department of Gastroenterology, Huashan Hospital Affiliated to Fudan University, Shanghai, China)

Wenjie YUE (Department of Gastroenterology, Huashan Hospital Affiliated to Fudan University, Shanghai, China)

Turkish Journal of Gastroenterology

0 0

Yıl: 2019 Cilt: 30 Sayı: 2 Sayfa Aralığı: 132 - 138 Metin Dili: İngilizce İndeks Tarihi: 20-05-2019

How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?

Öz:

Background/Aims: To investigate how the serum 25-hydroxyvitamin D (25(OH)D) level change in patients with inflammatory boweldisease (IBD) and investigate the intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1) expressions.Materials and Methods: A total of 105 patients with IBD were enrolled in the present study, including 49 cases with ulcerative colitis (UC)and 56 cases with Crohn’s disease (CD), compared with 45 healthy controls (CON) during the same period by testing the permeability ofthe intestinal mucosa. The expressions of VDR and CYP27B1 in the intestinal mucosa were detected, so as the serum endotoxin, tumornecrosis factor (TNF)-α, and 25(OH)D levels.Results: The lactulose and mannitol absorption ratio (LMR) and serum endotoxin and TNF-α levels were significantly higher in the IBDgroup than in the CON group (p<0.05). The levels of LMR, endotoxin, and TNF-α were higher in the UC group than in the CD group, but25(OH)D was lower (p<0.05). VDR in the IBD and UC groups was down-regulated when compared with the CON group (p<0.05), but therewas no significance between them (p>0.05). CYP27B1 in the IBD and CD groups was significantly up-regulated compared with the CONgroup (p<0.05), with no significant difference between them (p>0.05).Conclusion: Patients with IBD exhibit vitamin D metabolism imbalance, lower serum 25(OH)D, and lower VDR expression, but higherCYP27B1 expression in the colonic mucosa. However, VDR and CYP27B1 cannot be used to distinguish UC and CD.

Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Büsch K, Sonnenberg A, Bansback N. Impact of inflammatory bowel disease on disability. Curr Gastroenterol Rep 2014; 16: 414. [CrossRef ]
Malik TA. Inflammatory Bowel Disease: Historical Perspective, Epidemiology, and Risk Factors. Surg Clin North Am 2015; 95: 1105-22. [CrossRef]
Fiocchi C. Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol 2015; 30(Suppl 1): 12-8. [CrossRef ]
Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol 2014; 20: 13863-78. [CrossRef]
Algaba A, Guerra I, Marín-Jiménez I, et al. Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohns Colitis 2015; 9: 326-33. [CrossRef ]
Gallinger ZR, Weizman AV. Colorectal cancer in inflammatory bowel disease: a shift in risk? Expert Rev Anticancer Ther 2014; 14: 847-56. [CrossRef]
Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013; 7: 322-37. [CrossRef]
Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis 2015; 9: 507-15. [CrossRef]
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42; quiz e30.
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-9. [CrossRef ]
Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol 2015; 50: 495-507. [CrossRef ]
Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81. [CrossRef ]
Chałupniak A, Waszczuk K, Hałubek-Głuchowska K, Piasecki T, Gotszalk T, Rybka J. Application of quartz tuning forks for detection of endotoxins and Gram-negative bacterial cells by monitoring of Limulus Amebocyte Lysate coagulation. Biosens Bioelectron 2014; 58: 132-7. [CrossRef ]
Lin AV. Indirect ELISA. Methods Mol Biol 2015; 1318: 51-9. [CrossRef]
Van Schoor NM, Heymans MW, Lips P. Vitamin D status in relation to physical performance, falls and fractures in the Longitudinal Aging Study Amsterdam: A reanalysis of previous findings using standardized serum 25-hydroxyvitamin D values. J Steroid Biochem Mol Biol 2017; 177: 255-60. [CrossRef ]
Palmer MT, Weaver CT. Linking vitamin d deficiency to inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2245-56. [CrossRef ]
Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996; 239: 131-7. [CrossRef ]
El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci 2011; 56: 825-9. [CrossRef ]
Hlavaty T, Krajcovicova A, Payer J. Vitamin D therapy in inflammatory bowel diseases: who, in what form, and how much? J Crohns Colitis 2015; 9: 198-209. [CrossRef ]
Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn’s disease. J Gastroenterol 2004; 39: 527-33. [CrossRef ]
Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environment alinfluences. Gastroenterology 2004; 126: 1504-17. [CrossRef ]
Soon IS, Molodecky NA, Rabi DM, Ghali WA, Barkema HW, Kaplan GG. The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterol 2012; 12: 51. [CrossRef ]
Hochberg Z. Rickets-past and present. Introduction. Endocr Dev 2003; 6: 1-13. [CrossRef ]
Khalili H, Huang ES, Ananthakrishnan AN, et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 2012; 61: 1686-92. [CrossRef ]
Farraye FA, Nimitphong H, Stucchi A, Dendrinos K, Boulanger AB, Vijjeswarapu A, et al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn’s disease. Inflamm Bowel Dis 2011; 17: 2116-21. [CrossRef]
Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004; 53: 1129-36. [CrossRef ]
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24. [CrossRef ]
Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007; 8: 5. [CrossRef ]
Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17: 2386-92. [CrossRef ]
Liu W, Chen Y, Golan MA, et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest 2013; 123: 3983-96. [CrossRef ]
Liu N, Nguyen L, Chun RF, et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 2008; 149: 4799-808. [CrossRef ]
Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003; 102: 3314-6. [CrossRef ]
Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-52. [CrossRef ]
Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha, 25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35: 217-24. [CrossRef ]

APA	HUANG J, CHEN T, Liu Y, LYU L, LI X, YUE W (2019). How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. , 132 - 138.
Chicago	HUANG Jianping,CHEN Tao,Liu Yi,LYU Liyuan,LI Xiang,YUE Wenjie How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. (2019): 132 - 138.
MLA	HUANG Jianping,CHEN Tao,Liu Yi,LYU Liyuan,LI Xiang,YUE Wenjie How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. , 2019, ss.132 - 138.
AMA	HUANG J,CHEN T,Liu Y,LYU L,LI X,YUE W How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. . 2019; 132 - 138.
Vancouver	HUANG J,CHEN T,Liu Y,LYU L,LI X,YUE W How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. . 2019; 132 - 138.
IEEE	HUANG J,CHEN T,Liu Y,LYU L,LI X,YUE W "How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?." , ss.132 - 138, 2019.
ISNAD	HUANG, Jianping vd. "How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?". (2019), 132-138.

APA	HUANG J, CHEN T, Liu Y, LYU L, LI X, YUE W (2019). How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. Turkish Journal of Gastroenterology, 30(2), 132 - 138.
Chicago	HUANG Jianping,CHEN Tao,Liu Yi,LYU Liyuan,LI Xiang,YUE Wenjie How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. Turkish Journal of Gastroenterology 30, no.2 (2019): 132 - 138.
MLA	HUANG Jianping,CHEN Tao,Liu Yi,LYU Liyuan,LI Xiang,YUE Wenjie How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. Turkish Journal of Gastroenterology, vol.30, no.2, 2019, ss.132 - 138.
AMA	HUANG J,CHEN T,Liu Y,LYU L,LI X,YUE W How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. Turkish Journal of Gastroenterology. 2019; 30(2): 132 - 138.
Vancouver	HUANG J,CHEN T,Liu Y,LYU L,LI X,YUE W How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?. Turkish Journal of Gastroenterology. 2019; 30(2): 132 - 138.
IEEE	HUANG J,CHEN T,Liu Y,LYU L,LI X,YUE W "How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?." Turkish Journal of Gastroenterology, 30, ss.132 - 138, 2019.
ISNAD	HUANG, Jianping vd. "How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)?". Turkish Journal of Gastroenterology 30/2 (2019), 132-138.